Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Consensus Price Target from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given an average rating of “Moderate Buy” by the fifteen brokerages that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $55.64.

KYMR has been the subject of several analyst reports. UBS Group lowered their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Morgan Stanley raised their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Leerink Partners reaffirmed an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. The trade was a 5.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.82% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Blue Trust Inc. raised its position in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares in the last quarter. State of Wyoming bought a new stake in Kymera Therapeutics during the 4th quarter valued at $45,000. Values First Advisors Inc. bought a new stake in Kymera Therapeutics during the 3rd quarter valued at $61,000. GF Fund Management CO. LTD. bought a new stake in Kymera Therapeutics during the 4th quarter valued at $55,000. Finally, Quarry LP bought a new stake in Kymera Therapeutics during the 3rd quarter valued at $95,000.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $36.81 on Monday. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -15.73 and a beta of 2.18. Kymera Therapeutics has a 1 year low of $29.24 and a 1 year high of $53.27. The business has a 50 day simple moving average of $39.77 and a 200-day simple moving average of $44.07.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.